Bec Roldan

Oct 8, 2024 | boisestatepublicradio.org | Bec Roldan

A leading national survey finds that 22% of LGBTQ+ women respondents have attempted suicide, and 66% reported seeking treatment for trauma. “The trauma burden in this community is enormous,” said Jaime Grant, one of the researchers who conducted the survey. These findings are included in a report released Tuesday from the Urvashi Vaid National LGBTQ+ Women’s Community Survey, named after the late lesbian activist.

Oct 8, 2024 | wlrn.org | Bec Roldan

A leading national survey finds that 22% of LGBTQ+ women respondents have attempted suicide, and 66% reported seeking treatment for trauma. “The trauma burden in this community is enormous,” said Jaime Grant, one of the researchers who conducted the survey. These findings are included in a report released Tuesday from the Urvashi Vaid National LGBTQ+ Women’s Community Survey, named after the late lesbian activist.

Oct 8, 2024 | wlrn.org | Bec Roldan

A leading national survey finds that 22% of LGBTQ+ women respondents have attempted suicide, and 66% reported seeking treatment for trauma. “The trauma burden in this community is enormous,” said Jaime Grant, one of the researchers who conducted the survey. These findings are included in a report released Tuesday from the Urvashi Vaid National LGBTQ+ Women’s Community Survey, named after the late lesbian activist.

Oct 8, 2024 | npr.org | Bec Roldan

LGBTQ+ women face disproportionate rates of mental health issues and barriers to careA leading national survey finds that 22% of LGBTQ+ women respondents have attempted suicide, and 66% reported seeking treatment for trauma. “The trauma burden in this community is enormous,” said Jaime Grant, one of the researchers who conducted the survey. These findings are included in a report released Tuesday from the Urvashi Vaid National LGBTQ+ Women’s Community Survey, named after the late lesbian activist.

Sep 20, 2024 | cen.acs.org | Bec Roldan

In 2020, Carlos A. Martinez and his team at Pfizer were racing to massively scale up production of nirmatrelvir, a key component of the COVID-19 antiviral Paxlovid. While it can take years for a drug candidate to make it to patients, Pfizer brought nirmatrelvir to market in only 17 months ( ACS Cent. Sci. 2023, DOI: 10.1021/acscentsci.3c00145).